Here, we aim to characterize the MAPT locus in the AJ population, determine whether its association with PD and its effect size depends on a patient’s carrier state (patients carrying either GBA1 mutations or LRRK2-G2019S mutation, and non-carriers of these mutations), and explore potential mechanisms responsible for this effect. This evidence concerns the gene LRRK2 and Parkinson disease.